The FT report highlights that Starboard argues that these moves, along with poor capital allocation, have contributed to Pfizer's stock dropping over 50% from its pandemic peak. The activist investor will likely push for significant changes, possibly including a leadership overhaul or further divestitures. With Pfizer's stagnant revenue growth and limited options for quick fixes, Starboard's path to reshaping the company remains uncertain. Pfizer has already implemented cost-cutting measures and sold off divisions, leaving few levers for change. Price Action: PFE stock is up 0.31% at $29.53 during the premarket session at last check Wednesday. Read Next: Photo via Shutterstock